Endocrine Abstracts

Introduction: Adrenal insufficiency is a life-threatening disease. Conventional treatment requires multiple daily doses of immediate-release hydrocortisone or cortisone acetate causing non-physiological peaks and nadir of cortisol and it has been also associated with premature mortality, high frequency of infections, reduced quality of life, altered metabolic profile and reduced bone mineral density. A modified-release hydrocortisone (Plenadren®, Shire) by combining a rap...

Background: MicroRNAs (miRNAs) are small non-protein encoding RNAs which negatively regulate gene expression. Tissue miRNA profiles may be useful to distinguish benign from malignant lesions. Recently, we have identified in the serum of a retrospective series of patients, with benign nodular goiter (n=80) and papillary thyroid cancer (PTC: n=79), two miRNAs (-190 and -95) that in combination (providing the risk of malignancy defined as pmiRNA) allow the diffe...

Introduction: MicroRNAs (miRNAs) are small, endogenous, non-coding RNAs that act as negative regulators of gene expression. The miRNA expression is impaired in many types of human cancer including thyroid cancer. The tissue profile of miRNAs has been shown to be useful for differentiating benign from malignant thyroid nodules, however attainment of tissue samples requires an invasive procedure while blood sampling is minimally invasive and easy to obtain. The aim of this study...

Background: Conventional treatment (cortisone acetate or hydrocortisone) of adrenal insufficiency (AI) is potentially associated with glycometabolic alterations, bone loss and reduced quality of life. There is an increasing evidence of a more physiological replacement therapy with modified-release hydrocortisone (Plenadren).AimThe objectives of our study were: 1) to compare the gene expression profile of patients under conventional treatment and Plenadren versus healthy contro...